Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 29

1.

Predicting treatment outcome following 24 weeks peginterferon alpha-2a/ribavirin therapy in patients infected with HCV genotype 1: utility of HCV-RNA at day 0, day 22, day 29, and week 6.

Lukasiewicz E, Hellstrand K, Westin J, Ferrari C, Neumann AU, Pawlotsky JM, Schalm SW, Zeuzem S, Veldt BJ, Hansen BE, Verhey-Hart E, Lagging M.

Hepatology. 2007 Jan;45(1):258-9. No abstract available.

PMID:
17187414
2.

Peginterferon and ribavirin for chronic hepatitis C.

Hoofnagle JH, Seeff LB.

N Engl J Med. 2006 Dec 7;355(23):2444-51. Review. No abstract available.

PMID:
17151366
3.

Optimal therapy in genotype 1 patients.

Farnik H, Mihm U, Zeuzem S.

Liver Int. 2009 Jan;29 Suppl 1:23-30. doi: 10.1111/j.1478-3231.2008.01969.x. Review.

PMID:
19207963
4.

Viral hepatitis C.

Poynard T, Yuen MF, Ratziu V, Lai CL.

Lancet. 2003 Dec 20;362(9401):2095-100. Review.

PMID:
14697814
5.

New HCV therapies on the horizon.

Vermehren J, Sarrazin C.

Clin Microbiol Infect. 2011 Feb;17(2):122-34. doi: 10.1111/j.1469-0691.2010.03430.x. Review.

6.

Current therapy for hepatitis C: pegylated interferon and ribavirin.

McHutchison JG, Fried MW.

Clin Liver Dis. 2003 Feb;7(1):149-61. Review.

PMID:
12691464
7.

A perspective on modelling hepatitis C virus infection.

Guedj J, Rong L, Dahari H, Perelson AS.

J Viral Hepat. 2010 Dec;17(12):825-33. doi: 10.1111/j.1365-2893.2010.01348.x. Epub 2010 Aug 15. Review.

8.

[Guidelines for treatment of hepatitis C].

Iino S.

Nihon Rinsho. 2004 Jul;62 Suppl 7(Pt 1):342-6. Review. Japanese. No abstract available.

PMID:
15359818
9.

The role of genetic markers in hepatitis C virus therapy: a major step for individualized care.

McHutchison JG.

Liver Int. 2011 Jan;31 Suppl 1:29-35. doi: 10.1111/j.1478-3231.2010.02389.x. Review.

PMID:
21205135
10.

[Experimental therapy in HCV infection].

Inglot M, Gładysz A, Rymer W.

Przegl Epidemiol. 2005;59(2):525-33. Review. Polish.

PMID:
16190563
11.

Management of hepatitis c genotype 4 in the liver transplant setting.

Al-Hamoudi WK.

Saudi J Gastroenterol. 2016 May-Jun;22(3):173-82. doi: 10.4103/1319-3767.182453. Review.

12.

[Assessment and monitoring of patients with chronic hepatitis C on antiviral therapy--state of the art in 2003].

Simon K, Szymczak A.

Pol Arch Med Wewn. 2004 Jul;112(1):891-8. Review. Polish. No abstract available.

PMID:
15526854
13.

[Long-acting interferon: studies on pegylated interferon].

Ma H, Wang H.

Zhonghua Gan Zang Bing Za Zhi. 2002 Feb;10(1):78-9. Review. Chinese. No abstract available.

PMID:
11856520
14.

Effect of HCV viral dynamics on treatment design: lessons learned from HIV.

Bain VG.

Am J Gastroenterol. 2001 Oct;96(10):2818-28. Review.

PMID:
11693314
15.

Epidemiology and treatment outcomes of patients with chronic hepatitis C and genotypes 4 to 9.

Nguyen MH, Keeffe EB.

Rev Gastroenterol Disord. 2004;4 Suppl 1:S14-21. Review.

PMID:
15184820
16.

[Changes in the management of patients with side effects from the treatment of hepatitis C].

Bezemer G, Schalm SW, van Gool AR, de Knegt RJ.

Ned Tijdschr Geneeskd. 2007 Mar 3;151(9):525-30. Review. Dutch.

PMID:
17373393
17.

Genetic diversity of the hepatitis C virus: impact and issues in the antiviral therapy.

Le Guillou-Guillemette H, Vallet S, Gaudy-Graffin C, Payan C, Pivert A, Goudeau A, Lunel-Fabiani F.

World J Gastroenterol. 2007 May 7;13(17):2416-26. Review.

18.

Modeling HCV kinetics under therapy using PK and PD information.

Shudo E, Ribeiro RM, Perelson AS.

Expert Opin Drug Metab Toxicol. 2009 Mar;5(3):321-32. doi: 10.1517/17425250902787616 . Review.

19.

Peginterferon alfa-2a (40KD): a potent long-acting form of interferon alfa-2a for the treatment of hepatitis C.

Modi MW, Lamb MW, Shiomi M.

Adv Exp Med Biol. 2003;519:59-67. Review. No abstract available.

PMID:
12675208
20.

Hepatitis C (chronic).

Mohsen A, Norris S.

Clin Evid. 2006 Jun;(15):1061-72. Review. No abstract available.

PMID:
16973044

Supplemental Content

Support Center